Barry Ticho, M.D., Ph.D., FACC

Barry Ticho is the chief medical officer at Stoke Therapeutics, where he leads clinical development, clinical development operations, pharmacovigilance, toxicology, translational DMPK and clinical pharmacology and ophthalmology research.

Barry has more than 25 years of experience in research and clinical development in the biotechnology industry. Prior to joining Stoke, Barry was the head of research and development, cardiovascular and metabolic diseases at Moderna Therapeutics, where he specialized in mRNA treatments. Before that, he was the head of external R&D innovation in the Cardiovascular and Metabolic Disease Research Unit at Pfizer.  Previously, Barry was vice president of clinical development at Biogen. He was also co-founder, founding CEO and board member of Verve Therapeutics. Barry is a member of the Scientific Advisory Board of Cardior Pharmaceuticals, and a member of the advisory boards for Sania Therapeutics and mana.bio.

Barry obtained his M.D. and Ph.D. degrees from the University of Chicago. He completed pediatrics training at Northwestern University and a cardiology fellowship at Boston Children’s Hospital. Barry served as a member of the clinical staff at Harvard Medical School and Massachusetts General Hospital, where he conducted laboratory research on the regulation of cardiac development.